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Abstract We investigated the direct effects of growth
hormone (GH) replacement therapy (GH-RT) on he-
matopoiesis in children with GH deficiency (GHD) with
the special emphasis on proliferation and cell cycle
regulation. Peripheral blood (PB) was collected from sixty
control individuals and forty GHD children before GH-RT
and in 3rd and 6th month of GH-RT to measure hemato-
logical parameters and isolate CD34?-enriched he-
matopoietic progenitor cells (HPCs). Selected parameters
of PB were analyzed by hematological analyzer. Moreover,
collected HPCs were used to analyze GH receptor (GHR)
and IGF1 expression, clonogenicity, and cell cycle activity.
Finally, global gene expression profile of collected HPCs
was analyzed using genome-wide RNA microarrays. GHD
resulted in a decrease in several hematological parameters
related to RBCs and significantly diminished clonogenicity
of erythroid progenies. In contrast, GH-RT stimulated in-
creases in clonogenic growth of erythroid lineage and RBC
counts as well as significant up-regulation of cell cycle-
propagating genes, including MAP2K1, cyclins D1/E1,
PCNA, and IGF1. Likewise, GH-RT significantly modified
GHR expression in isolated HPCs and augmented systemic
IGF1 levels. Global gene expression analysis revealed
significantly higher expression of genes associated with
cell cycle, proliferation, and differentiation in HPCs from
GH-treated subjects. (i) GH-RT significantly augments cell
cycle progression in HPCs and increases clonogenicity of
erythroid progenitors; (ii) GHR expression in HPCs is
modulated by GH status; (iii) molecular mechanisms by
which GH influences hematopoiesis might provide a basis
for designing therapeutic interventions for hematological
complications related to GHD.
Keywords Hematopoietic stem/progenitor cells 
Hematopoiesis  Growth hormone deficiency  Growth
hormone deficiency in children
Introduction
Growth hormone (GH) is a pleiotropic hormone important
for modulation of physiological processes [1]. Importantly,
GH exerts its anabolic effects largely indirectly via
stimulation of insulin-like growth factor-1 (IGF1) produc-
tion. However, acting in autocrine/paracrine manner, GH
binds to the specific receptor (GHR), which induces in-
tracellular signaling pathways leading to differential gene
expression [1]. The classical examples of IGF1-indepen-
dent actions mediated through GHR include ovarian pre-
antral follicle development [2] or activation of chondrocyte
stem cells for chondrocyte generation at bone growth plate
[3]. Similarly, in vitro studies indicate that neural stem cell
activation by GH does not require IGF1 [4].
GH is also a potent modulator of hematopoietic system,
which has been described in numerous experimental stud-
ies. GH binds to GHR expressed on hematopoietic/immune
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cells and regulates their proliferation and differentiation [5,
6]. GH was shown to augment in vitro erythropoiesis [7],
granulopoiesis [8], and lymphopoiesis [9]. Likewise, sup-
plementation with recombinant human GH (rhGH) was
reported to reverse the age-induced hypocellularity of bone
marrow in old rats [10]. rhGH administered to mice or non-
human primates following lethal irradiation accelerated
their hematopoietic recovery [11].
Isolated GHD (IGHD) is a rare disease and its final
diagnosis is classically based on auxological and laboratory
criteria, including short stature, reduced growth velocity,
delayed bone age, and low GH responses to at least two
pharmacological stimuli [12]. GHD patients exhibit nu-
merous abnormalities in the hematological parameters of
peripheral blood (PB), including microcytosis, anisocyto-
sis, and poikilocytosis [13]. Furthermore, GHD patients
commonly suffer from certain types of anemia, which are
described in the literature as ‘‘IGHD-related anemia’’ [14].
The number of white blood cells is often reduced [15]. It
was demonstrated that the metabolic abnormalities typical
of GHD may be reversed by GH replacement therapy (GH-
RT) [16]. However, the exogenous administration of rhGH,
which has paracrine functions, does not necessarily mimic
the physiological activity of GH, and the precise biological
activity of rhGH requires further study. Data regarding
rhGH-induced modulation of hematopoiesis during GH-RT
are very limited, and only a few studies have evaluated the
relationship between GHD and hematological parameters
in children [17–20].
Therefore, we assessed the clinical outcomes of inap-
propriate GH signaling in CD34?-enriched hematopoietic
stem and progenitor cells collected from IGHD children. In
addition, we evaluated the effects of 6-month GH-RT on
proliferation and differentiation of CD34? cells and re-
covery of PB parameters.
Materials and methods
Subjects
We enrolled 40 children with severe IGHD, who were di-
agnosed according to the clinical criteria [12]. rhGH ther-
apy was administered by subcutaneous injection at
0.031 mg/kg/d. None of the patients suffered from diabetes
insipidus, chromosomal abnormalities, dysmorphic syn-
dromes, intestinal malabsorption, other chronic diseases, or
acquired GHD, as confirmed by a full clinical and
laboratory evaluation. 60 children of similar ages, who did
not differ significantly in terms of puberty and bone age,
constituted the control group. All procedures were ap-
proved by local ethics committee, and informed consent
was provided for each patient.
Laboratory measurements and cell isolation
PB samples were collected at the moment of GHD diag-
nosis and after 3 and 6 months of GH-RT. We determined
hematological and hormonal parameters and isolated
CD34?-enriched hematopoietic progenitor cells (HPCs).
The selected hematological parameters were evaluated
using cell analyzer (Cell Dyn 3000, Abbott Diagnostics).
The mononuclear cell fraction was isolated by density
gradient centrifugation and depleted of adherent and T
cells. This fraction was next enriched for CD34? cells
using the CD34 MicroBead Kit (Miltenyi Biotech, USA)
according to the manufacturer’s protocol.
RNA isolation and gene expression analysis
Total mRNA was isolated from HPCs using the RNeasy
Mini Kit (Qiagen, USA). Subsequently, mRNA was re-
verse transcribed using the First Strand cDNA Synthesis
Kit (Fermentas International Inc., Canada). Quantitative
assessment of GHR, MAP2K1, Cyclin D1, Cyclin E1,
PCNA, and IGF1 mRNA levels was performed using real-
time QRT-PCR carried out on a Bio-Rad CFX96 Real-
Time PCR Detection System (Bio-Rad Inc., USA). The 25
lL reaction mixture contained 12.5 lL of SYBR Green
PCR Master Mix, 10 ng of cDNA template, and one pair of
the primers listed in Supplementary Table 1. The relative
quantification value of the target gene was normalized to
the endogenous control gene (BMG) and expressed as 2DCt,
where DCt = [Ct of endogenous control gene] - [Ct of
target gene].
Flow cytometry
CD34? HPCs and lymphocytes were analyzed with respect
to the GHR expression. Briefly, erythrocytes in PB samples
were lysed using BD PharmLyse Lysing Solution (BD
Biosciences) for 15 min to obtain nucleated cells (NC). A
total of 1 9 106 NCs were incubated with mouse anti-hu-
man fluorochrome-conjugated monoclonal antibodies
against specific antigens, including GHR, CD34, and CD45
(all from BD Biosciences) and analyzed by flow cytometry
(LSRII, BD Biosciences). At least 0.5 9 106 cells with the
appropriate ratio of forward scatter to side scatter were
acquired for the analysis.
Clonogenic in vitro assays
CD34? HPCs were evaluated using in vitro clonogenic
assays. Briefly, 2 9 104 cells were resuspended in
0.4 mL of RPMI-1640 medium (Sigma Aldrich, USA)
and mixed with 1.8 mL of MethoCult HCC-4230
(StemCell Technologies Inc., Canada) supplemented with
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L-glutamine and antibiotics. To stimulate granulocyte–
macrophage colony-forming units (CFU-GM), IL-3
(20 U/mL), SCF (10 ng/mL), and GM-CSF (5 ng/mL)
were used. EPO (5 U/mL) and SCF (10 ng/mL) were
used for induction of erythrocyte burst-forming units
(BFU-E). IL-7 (5 ng/mL) and SCF (10 ng/mL) (all from
R&D System) were used for induction of B-lymphocyte
colony-forming units (CFU-B lymph). Each clonogenic
test was performed in quadruplicate.
Cell cycle analysis
Cell cycle progression in CD34? HPCs was analyzed using
the APO-Direct kit (BD Biosciences) according to the
manufacturer’s instructions.
ELISA
The systemic levels of IGF1 were measured using com-
mercially available, high-sensitivity ELISA Quantikine
human immunoassay kit (R&D Systems, USA) according
to the manufacturer’s instructions.
RNA isolation and Affymetrix GeneChip
microarray and data analysis
Total RNA was isolated from CD34? HPCs using
RNeasy Mini Kit (Qiagen, USA). RNA was isolated from
CD34? cells of five GH-treated patients, the same at
baseline, and in 3rd and 6th months of treatment, and of
five control subjects, and was pooled to generate the final
RNA sample representing a particular group in subse-
quent experimental procedures. Sense-strand cDNA gen-
erated from total RNA using an Ambion WT Expression
Kit (Life Technologies, UK) was fragmented and labeled
using the GeneChipH WT Terminal Labeling Kit (Affy-
metrix, USA) and hybridized onto an Affymetrix WT
Array Strip. Hybridization as well as subsequent fluidics
and scanning steps were performed using an Affymetrix
GeneAtlasTM system (Affymetrix). Differences in the
expression of the chosen genes and Gene Ontology (GO)
terms were analyzed in the R programming environment
using Bioconductor packages.
Statistical methods
Differences in the values of the quantitative pa-
rameters were compared between groups by unpaired
Student’s t test with Welch’s correction; for non-
parametric tests, values were compared using the
Mann–Whitney test. A P value of \0.05 was consid-
ered statistically significant.
Results
Characteristics of the clinical parameters
The characteristics of the subjects enrolled in the study are
summarized in Table S2.
Changes in the hematological parameters of patients
with GHD
Selected PB parameters were measured at diagnosis and
after 6 months of GH-RT as well in the control group
(Table 1). Subjects were divided into two groups, 4–10
(‘‘younger’’) and 11–17 (‘‘older’’) years of age, due to
common age-dependent changes in hematological pa-
rameters. We detected significantly decreased values of
RBCs, HGB, and HCT, regardless of age, in untreated
GHD patients compared to controls. Similarly, the GHD
patients (11–17 years of age) exhibited significantly
smaller MCH values, indicating a hypochromic state of
RBCs. Moreover, GHD patients (4–10 years of age) ex-
hibited significantly diminished MCV values, indicating
microcytosis. In the same manner, we compared GHD
patients before therapy and after 6 months of GH-RT and
noticed a significant increase of RBCs, HGB, HCT, and
MCV values after GH-RT, regardless of age. Finally, a
statistically significant increase in MCH value was ob-
served; however, this difference was only detected in
younger GH-treated children. Of note, we were not able to
detect any significant changes in platelets or WBCs in any
of the analyzed groups. These data indicate that GH-RT
could influence the morphological and functional changes
in cells of erythropoietic lineage in GHD patients.
GHR is expressed at the mRNA level in HPCs
from GHD patients and is modulated by GH therapy
Cells from all examined groups expressed GHR mRNA,
We observed a strong around 300 % up-regulation of GHR
mRNA in CD34? HPCs collected after 6 months of GH-
RT (P\ 0.001; Fig. 1) and its brisk 50 % up-regulation
after 3 months of GH-RT (P\ 0.05; Fig. 1), compared to
GHD patients before therapy. These data indicate that GHR
expression could be influenced by GH therapy; thus, it may
regulate GH-dependent effects in HPCs.
The number of GHR1 hematopoietic cells increases
during GH-RT in GHD patients
Next, we investigated the relationship between GHR? he-
matopoietic cell numbers and GH status. We simultane-
ously evaluated the number of GHR? HPCs and GHR?
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lymphocytes in PB before and during GH-RT (Fig. 2). We
observed a significantly higher percentage of circulating
GHR? HPCs in patients after 6 months of GH-RT relative
to GHD patients before therapy and controls (Fig. 2a). We
also observed a slight, but insignificant, increase in the
percentage of GHR? HPCs in GHD patients after first
3 months of GH-RT (Fig. 2a). Similarly, we detected sig-
nificantly increased percentage of GHR? lymphocytes in
GHD patients after 6 months of GH-RT relative to GHD
patients before therapy (Fig. 2b); importantly, the latter
group exhibited significantly decreased numbers of GHR?
lymphocytes compared to controls (Fig. 2b). The kinetics
of the number of GHR? HPCs detected during GH-RT
largely mimicked the pattern of GHR mRNA expression
detected in HPCs.
Increased clonogenicity of BFU-E, but not CFU-GM
or CFU-B lymph, from CD341-enriched HPCs
during the course of GH-RT
Subsequently, we examined the clonogenic potential of
CD34? HPCs in vitro. In GHD group, the number of
CD34?-expanded erythroid BFU-E colonies was sig-
nificantly lower than that observed in controls (72 vs.
100 %, respectively; P\ 0.05; Fig. 3). Furthermore, we
noted significantly increased clonogenicity of BFU-E
colonies grown from the HPCs collected after 6 months of
GH-RT, compared to those collected before GH-RT (108
vs. 72 %, respectively; P\ 0.05; Fig. 3). These findings
suggest that GH is involved in the systemic modulation of
erythropoiesis in GHD patients. We also assessed the
clonogenicity of CFU-GM and CFU-B lymph from HPCs
Table 1 Selected blood parameters in patients recruited for the study
Parameter Age-matched GHD patients GHD—before GH therapy
Mean ± SD




RBC (106/mm3) Younger 4,55 ± 0.08# 4.85 ± 0.08** 4.76 ± 0.06
Older 4.58 ± 0.06# 4.86 ± 0.07** 4.86 ± 0.09
HGB (g/dl) Younger 12.01 ± 0.26# 13.18 ± 0.23** 12.95 ± 0.23
Older 12.86 ± 0.09### 13.88 ± 0.19**** 13.91 ± 0.29
HCT (%) Younger 35.29 ± 0.56# 38.52 ± 0.67*** 37.26 ± 0.66
Older 37.60 ± 0.43### 40.60 ± 0.56*** 40.65 ± 0.70
MCV (mm3) Younger 76.99 ± 0.58## 79.38 ± 0.84* 82.01 ± 1.79
Older 81.42 ± 0.71 84.04 ± 0.84* 81.62 ± 1.05
MCH (pg) Younger 26.30 ± 0.36 27.09 ± 0.26 27.63 ± 0.61
Older 27.85 ± 0.31# 28.83 ± 0.31* 28.81 ± 0.34
MCHC (g/dl) Younger 34.16 ± 0.32 34.21 ± 0.26 34.30 ± 0.44
Older 34.25 ± 0.26 34.08 ± 0.23 34.06 ± 0.30
PLT (105/mm3) Younger 322.9 ± 11.89 313.8 ± 23.34 279.6 ± 17.30
Older 285.5 ± 9.68 260.9 ± 8.35 254.3 ± 15.14
WBC (103/mm3) Younger 7.81 ± 0.51 7.853 ± 0.58 8.21 ± 0.68
Older 6.386 ± 0.25 6.130 ± 0.23 7.131 ± 0.39
* P\ 0.05; ** P\ 0.01; *** P\ 0.001; **** P\ 0.0001 vs. values of GHD patients before therapy
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Fig. 1 Expression of GHR mRNA in CD34? HPCs of controls and
GHD patients at different time points. Results are expressed as the
mean value ± SD, *P\ 0.05; ***P\ 0.001 vs. GHD patients before
therapy
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collected from all groups, but observed no significant
changes (Fig. 3b, c).
GH-RT induces cell cycle progression in CD341-
enriched HPCs from GHD patients
We also investigated whether GH may play a role in
modulation of the cell cycle in HPCs following GH-RT. The
cell cycle activity in HPCs was measured by the detection of
cell cycle phases, i.e., the G1, S, and G2/M. We observed a




































































































Fig. 2 The percentage of GHR? HPCs (a) and GHR? lymphocytes
(b) of controls and GHD patients at different time points. The results
are expressed as the mean value ± SD. *P\ 0.05; **P\ 0.01 vs.





















































































































































Fig. 3 Comparative analysis of BFU-E (a), CFU-GM (b), and CFU-
B lymph (c) clonogenicity of CD34? HPCs from controls and GHD
patients at different time points. The results are expressed as the
percentage of the control value, which was set at 100 %. The results
are presented as the mean value ± SD. *P\ 0.05 vs. GHD patients
before therapy; #P\ 0.05 vs. control group
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GHD patients after 3 (P\ 0.05) and 6 (P\ 0.01) months of
GH-RT (Fig. 4a). GH treatment also generated an increase
of approximately 50 % of the population of HPCs in the G2/
M phase (3rd and 6th months of GH-RT) and S phase (6th
month of GH-RT) compared to untreated patients (Fig. 4b,
c). These data demonstrate the potential positive modulation
by GH-RT of G1 phase in CD34? cell cycle.
GH-RT up-regulates proliferation-related gene
expression in CD341 HPCs in GHD patients
GH promotes cell proliferation and differentiation. There-
fore, we investigated whether GH-RT plays a role in HPC
proliferation based on the analysis of the mRNA expression
of genes crucial for the induction (MAP2K1) and mainte-
nance (PCNA, CCND1, CCNE1) of cell proliferation. The
mRNA levels for all of the examined genes were sig-
nificantly higher in GHD patients after 3 and 6 months of
GH-RT compared to GHD patients before therapy and
controls. As shown in Fig. 5, there was around 300 % in-
crease in the mRNA expression of MAP2K1 and a similar
increase in the mRNA expression of CCND1. Furthermore,
we observed a nearly 100 % increase in CCNE1 expression
and a nearly 30 % increase in PCNA expression. These
findings suggest that GH might be partially involved in the
mechanisms responsible for induction of proliferation in
HPCs from GHD patients treated with GH-RT.
GH-RT modulates the IGF1 gene and protein
expression in GHD patients
Finally, we decided to verify potential association between
GH therapy and expression of IGF1 in vivo. The mean sys-
temic concentrations of IGF1 in GHD patients and control
individuals are depicted in Fig. 6a. We found that the levels
of IGF1were significantly higher inGH-treated patients than
those before therapy. Interestingly, systemic mean levels of
IGF1 significantly differed between untreated GHD patients
and their controls. Our data reveal that therapeutic inter-
vention with rhGH provided to GHD patients could augment
the global IGF1 production. In order to more extensively
examine the expression of IGF1 in PB-derived CD34?HPCs
and to determinewhether GH-RT could affect the IGF1 gene
transcription, we analyzed the levels of IGF1 gene expres-
sion in HPCs collected from all examined groups. As shown
in Fig. 6b, the mRNA expression of IGF1 was significantly






















































































































































bFig. 4 Analysis of the cell cycle phases (G1, S, and G2?M) in
CD34? HPCs of controls and GHD patients at different time points.
The results are expressed as the mean value ± SD. *P\ 0.05;
**P\ 0.01 vs. GHD patients before therapy
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untreated patients and controls. No statistically significant
differences in terms of IGF1 mRNA levels were found in
comparison of the untreated GHD patients and controls.
These findings demonstrate that exogenous rhGH could
trigger IGF1 gene expression in CD34? HPCs from GHD
patients, which might have autocrine/paracrine impact on
proliferation and survival of these cells.
Whole-genome microarray analysis reveals large-
scale alterations in gene expression in CD341-
enriched HPCs in GHD patients during the course
of GH-RT
We analyzed the global gene expression pattern in CD34?-
enriched HPCs collected from GHD patients before GH
therapy and at selected time points (3 and 6 months post-
GH-RT) and from controls.. In the GHD patients treated
for 6 months with GH, we observed 177 genes that were
up-regulated at least twofold (P\ 0.05) (Table S3). The
most significantly up-regulated gene in this group was the
early activation antigen CD69 (CD69; 18-fold). CD69 is
involved in WBC proliferation and is a signal-transmitting
receptor in different subsets of WBCs. The other strongly
up-regulated genes in this group included the regulator of
G-protein signaling-1 (RGS1; 16-fold), which is involved
in B-cell proliferation; asparaginyl-tRNA synthetase
(NARS; tenfold), which belongs to the class II family of
tRNA synthetases; radical S-adenosyl methionine domain
containing 2 (RSAD2; ninefold), encoding viperin, which


















































































































































































Fig. 5 Expression of cell cycle-regulating genes in PB-derived
CD34? HPCs of controls and GHD patients at different time points.
mRNA expression of the MAP2K1 (a), PCNA (b), CCND1 (c), and
CCNE1 (d) genes was determined. mRNA levels are expressed in
arbitrary units as the mean value ± SD. **P\ 0.01; ***P\ 0.001
vs. GHD patients before therapy
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and pleckstrin (PLEK; sevenfold), which is the platelet and
leukocyte major protein C kinase substrate important for
HPC differentiation. Of interest, our analysis identified
several interleukins (IL) and related molecules (IL1A,
IL1B, IL8, ILF2, IL1RN, IL1R1, NFIL3, and IL5RA), as
well as chemokines (CXCL1, CXCL2, CXCL16, and CCL4)
and chemokine receptors (CXCR4, CXCR5, CCR4, and
CCRL2), as up-regulated after 6 months of GH-RT. On-
costatin M (OSM; fourfold), a growth regulator, was also
found to be over-expressed. Furthermore, we found that
several members of the zinc finger protein family, which
act as transcriptional regulators involved in mitosis and cell
development, including EGR3, ZRANB2, ZNF146,
RNF138, ZNF791, and ZNF766, were significantly up-
regulated after GH-RT. In contrast, in this group 21 genes
were significantly down-regulated (Table S4). Similarly,
we found that 3 months of GH treatment was responsible
for significant up-regulation of 64 genes (Table S5) and
down-regulation of 22 genes (Table S6). In addition, we
found that prolongation of GH therapy from 3 to 6 months
was responsible for significant up-regulation of 71 genes
(Table S7) and down-regulation of 146 genes (Table S8).
We also analyzed the differences in gene expression
profiles of untreated GHD patients compared to their
healthy controls and observed the significant up-regulation
of 16 genes (Table S9) and down-regulation of 129 genes
(Table S10). Interestingly, untreated GHD patients exhib-
ited significantly down-regulated expression of genes for
several ILs and IL-related proteins (IL1B, IL2RB, IL1R2,
IL7R, ILF2, and ITK) or chemokines and their receptors
(CXCL1, CCL4, CXCL16, CCR1, CXCR2, and CXCR1).
We also observed down-regulated genes involved in cell
cycle control (MAPK14, MDM2, and HCK), which in
general exhibit cytoprotective functions and are essential
for cell survival.
Subsequently, 90 genes were specifically up-regulated at
least twofold after 6-month GH-RT in GHD patients
compared to their controls (Table S11). The genes mostly
up-regulated during the course of GH-RT included inter-
feron-induced protein 44-like (IFI44L; ninefold) and in-
terferon-induced protein with tetratricopeptide repeats-1
(IFIT1; sevenfold), which are both members of the inter-
feron-related immune response signaling pathway. Of im-
portance, our analysis identified significant increases in the
expression of essential regulators of cell cycle progression,
such as CDK6, SPIN1, TBL1XR1,JUN and APEX1. More-
over, among the highly up-regulated genes, we observed
those related to the positive regulation of hematopoiesis,
including MYB, HPGDS, LY6E, and two markers of he-
matopoietic stem cells, CD133 (PROM1) and CD34. Fur-
thermore, we found that, in the same period, the GH
therapy induced the significant down-regulation of 45 ge-
nes (Table S12). In contrast, the 3-month-treatment with
GH was responsible for significant up-regulation of 21
genes (Table S13) and down-regulation of 26 genes (Table
S14).
Next, all of the differentially expressed genes were clas-
sified according to the GO classification of biological pro-
cesses. Functional analysis using GO revealed that a number
of pathways were specifically and diversely represented in
the CD34?-enriched HPCs from GHD patients and controls.
We observed that genes involved in the regulation of cell
proliferation, regulation of cytokine production, signal
transduction, regulation of angiogenesis and endothelial cell




























































































Fig. 6 The levels of IGF1 in peripheral blood (a) and the expression
of IGF1 mRNA in CD34? HPCs (b) of controls and GHD patients at
different time points. The results are expressed as the mean
value ± SD. **P\ 0.01; ***P\ 0.001 vs. GHD patients before
therapy; #P\ 0.05 vs. control group
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processes, regulation of gene expression, regulation of cell
death, regulation of cellular metabolic process, regulation of
homeostatic process, positive regulation of cellular pro-
cesses, positive regulation of cytokine production, regula-
tion of hormone transport and secretion, positive regulation
of defense responses, regulation of responses to stress,
wounding, and hypoxia were among the most up-regulated
duringGH-RT. A summary of the distribution of the selected
gene clusters according to the GO classification results is
presented in Fig. 7.
Discussion
While the role of GH in hematopoiesis has been studied in
several in vitro studies and animal models, the contribution
of GH to hematopoiesis in GHD patients undergoing rhGH
therapy remains incompletely understood. Although a
number of GH-regulated genes have been identified, genes
relating GH to the biology of HSPCs remain largely un-
known. Accordingly, we sought to investigate the effects of
6-month GH-RT on cell cycle and HPCs proliferation in
Fig. 7 Global gene expression
changes in CD34? HPCs of
controls and GHD patients at
different time points (before
GH-RT and in the 3rd and 6th
months of GH-RT). The
heatmap represents the
expression levels of highly
over-expressed genes (fold
change[2). Individual genes
are designated according to the
GO classification of specific
biological processes listed on
the left side of the graph. Each
column comprises a set of
horizontal lines, each
representing a single gene. The
levels of gene expression are
indicated on a color scale, with
yellow corresponding to the
highest level of expression and
blue corresponding to the lowest
level. The expression range of
the analyzed genes is shown
below the graph. The upper
diagram (a) depicts large-scale
alterations in gene expression
between HPCs collected in the
3rd and 6th months of GH-RT
compared to those collected
before GH-RT. The lower
diagram (b) presents large-scale
alterations in gene expression
between HPCs collected during
the course of GH-RT compared
to those collected before GH-
RT as well as HPCs obtained
from controls
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children with GHD. To our knowledge, the present study is
the first to evaluate CD34?-enriched HPC functions with
respect to GHD in children.
A considerable amount of evidence suggests that GH
plays an important role in the modulation of hematopoiesis
and exerts biological effects on erythropoiesis [7], granu-
lopoiesis [8], and lymphopoiesis [21]. Importantly, the
study of Sharma et al. on transgenic mice revealed that a
genetic 100-fold reduction in GH expression did not affect
hematopoietic cell expansion, maturation, or differentiation
[22]. However, it is challenging to apply results obtained
in vitro and in animal models to human physiology. As
GHR expression is a key target that influences the effec-
tiveness of GH, the analysis of its expression in HPCs is
invaluable. The expression of GHR at the mRNA and
protein levels was previously detected in human mature T
and B lymphocytes and monocytes/macrophages [23, 24].
However, there is a lack of studies providing the evidence
that GHR is expressed in CD34?-enriched HPCs from PB
of GHD children. We observed in our study that GH-RT
significantly augmented the basal expression levels of
mRNA for GHR. Similarly, Hattori et al. showed previ-
ously a significant positive correlation between GH con-
centration and mRNA expression for GHR in normal
human B lymphocytes cultured in vitro [23]. Lin et al.
reported that, in mice bearing subcutaneous tumors
naturally expressing GHR protein, the GHR mRNA ex-
pression was significantly increased after GH treatment
[25]. These results indicate that the expression of GHR
mRNA could be stimulated by increased GH concentra-
tions. Indeed, we observed increased GHR mRNA ex-
pression and percentage of GHR? HPCs in patients treated
with GH-RT for 6 months. Similarly, the population of
GHR? lymphocytes was increased significantly (P\ 0.01)
after GH-RT. Furthermore, we observed that the quantity
of GHR? lymphocytes in untreated GHD patients was
significantly decreased compared to that of controls. GH
exerts effects on cell survival and proliferation also through
its direct effects on several types of cells, including
chondrocyte progenitors [26]. To further explore the po-
tential direct GH influence on HPC proliferation and dif-
ferentiation, we assessed the effect of GH-RT on HPCs
clonogenicity. We demonstrated that clonogenic potential
of CD34?-expanded BFU-E was significantly higher in
GHD patients treated with GH-RT for 6 months than that
before therapy. It is possible that this effect might be a
result of the modulatory action of GH on the production of
erythropoietin (EPO), as increased concentrations of GH
augment the levels of EPO in GHD patients with developed
anemia [27, 28], possibly due to increased hepatic syn-
thesis of EPO [29]. However, in in vitro cultures containing
an established amount of EPO, we observed increased
growth only in the samples collected from patients treated
previously with GH-RT. Indeed, previous studies have
demonstrated that GH directly enhances the in vitro pro-
liferation of erythroid precursors [7], and GH therapy had a
stimulatory effect on the growth of BFU-E progenitors
collected from 11 children with IGHD [30]. The observed
significant increase in the reactivity of erythroid pro-
genitors from GHD children during GH-RT may be the
result of increased bioavailability of free, unbound GHR
molecules on the progenitor cell surface. Additionally, GH
may act as a potent direct cell growth stimulator, as shown
in vitro using murine Friend erythroleukemia cells and
human erythroleukemia cell line K562 [31, 32]. Taken
together, these data suggest that the GH/GHR biological
axis can directly induce signal transduction pathways in-
volved in HSPC proliferation distinct from EPO-dependent
pathways. This hypothesis is consistent with our another
finding that CD34? cells of GHD patients before therapy
exhibited considerable growth reduction of BFU-E com-
pared to those of the control subjects.
The GH-activated GHR induces pro-survival mechan-
isms downstream of the classical JAK-STAT pathway and
finally initiates target gene transcription, which may result
in increased stem cell cycling [33]. This potential
mechanism of direct GH action in HPCs strongly correlates
with our observations from the 3rd and 6th months of GH-
RT, showing significantly increased numbers of CD34?
cells in G1 phase of the cell cycle, together with consid-
erable increase of HPCs numbers in the S and G2?M
phases, indicating that the number of proliferating cells
might be increased during GH therapy. Likewise, GH si-
multaneously increased the mRNA expression of genes
involved in cell cycle regulation, such as MAP2K1, cyclins
D1 and E1, and PCNA, in CD34? HPCs from GH-treated
individuals. These data correlate strongly with the changes
in erythrocyte-related parameters including RBC, HCT,
HGB, MCV, and MCH measured in the PB. Importantly,
adult patients with GH deficiency have been characterized
in several studies as anemic patients [30, 34]. In our study,
at baseline the RBC numbers were decreased with reduced
MCV and MCH values. In contrast, these values increased
significantly within 6 months of GH-RT. Similarly, in the
clinical study of GHD adults performed by Christ et al., the
administration of GH led to an increase in RBC mass,
indicating that GH may have a direct in vivo regulatory
effect on erythropoiesis [35]. Additionally, Strauch et al.
reported that, in acromegalic patients, RBC mass was in-
creased but returned to normal values after curative surgery
[36]. On the other hand, GHD patients suffer from sig-
nificantly decreased HGB concentrations, regardless of
their age. Subsequently, the HGB levels were significantly
increased during GH-RT. Importantly, the final HGB
concentration measured in GH-treated patients was main-
tained within the normal ranges and did not exhibit any
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superphysiological concentrations, as it has been reported
after treatment with recombinant EPO [34]. Similarly,
Miniero et al. evaluated 279 children with IGHD and di-
agnosed moderate anemia in 48 patients [14]. Moreover,
the HGB levels significantly increased during GH-RT, and
all examined children exhibited normal HGB values after
48 months of GH therapy [14]. GH is believed to increase
the necessity for oxygen transport to the peripheral tissues
due to its general anabolic effects, potentially resulting in
increased HGB levels in PB. Together, these data support
the concept that the GH/GHR axis directly promotes ery-
thropoiesis in vivo in GHD children.
Although the liver is the major site of IGF-1 production
(70 %) after stimulation by GH, IGF-1 is also produced lo-
cally by peripheral cells under basal conditions and in re-
sponse to different stimuli [37]. Thus, local production of
IGF1 also plays a role in the growth and differentiation of
tissues, and several studies established the critical impor-
tance of IGF action for the development and normal function
of hematopoietic system. It was demonstrated that IGF1
stimulates the growth, proliferation, and survival of different
hematopoietic cell populations in vitro and inhibits their
apoptosis [reviewed in detail in 38].Moreover, Tsarfaty et al.
observed that human IGF1 promotes hematopoietic growth
in vivo in mice [15]. Likewise, GH and IGF1 administration
enhanced reconstitution of the immune system and he-
matopoiesis after marrow transplantation in mice [39, 40].
Alpdogan et al. demonstrated that lymphoid and myeloid
reconstitution after marrow transplantation was enhanced by
IGF1 administration through the expansion of thymic pre-
cursor cell populations [41]. Vidal et al. reported that IGF1
was in the group of 52 acutelyGH-activated genes in the liver
2 h after GH treatment [42]. Further analyses in mice with a
targeted deletion of GHR have confirmed its key roles in
controlling of IGF1 production [43]. In this notion, we
conducted a preliminary analysis of the potential influence of
GH-RT on IGF1mRNA expression in CD34 ? HPCs from
GHD patients and found that GH therapy significantly
elevated its levels compared to GHD patients before therapy
and controls. We also found the significantly higher IGF1
concentration in PB of GHD patients in course of GH-RT,
which is in agreement with previous studies [44, 45]. From
the molecular stand point, increased levels of IGF1 might be
caused by several molecular mechanisms, which are GH
dependent [46] and GH independent [47], with the liver as
the main source of circulating hormone. However, our study
demonstrates that CD34?HPCs can be a GH-dependent
source of IGF1, which next may play pro-survival role and
could potentially stimulate HPC proliferation in au-
tocrine/paracrine manner. Moreover, we have found that
exogenous GH is biologically active in CD34? HPCs and
stimulates the appropriate signal transduction pathways
through GH/GHR signaling in these cells.
Finally, we have demonstrated for the first time that GH
treatment is associated with specific changes in the global
pattern of gene expression, which triggers diverse signaling
pathways within HPCs from GHD children. A total of 177
genes were found to be differentially expressed after
6-month GH therapy compared to subjects before treat-
ment. These genes were mainly associated with biological
processes such as the regulation of cell cycle progression
and mitosis, cell proliferation, hematopoietic and immune
cell proliferation, maturation and differentiation, general
cell development and differentiation, the regulation of
translation, mRNA processing, cell migration and adhe-
sion, cytokine secretion, intracellular and extracellular
signaling pathways, cell metabolism, cell chemotaxis, an-
giogenesis, and apoptosis inhibition (Fig. 7a). Interesting-
ly, our microarray experiments revealed that the three most
strongly up-regulated genes were involved in hematopoi-
etic T- and B-cell proliferation, activation, and differen-
tiation. The above results could indicate that these GH-
dependent changes in immune networks may improve
immune functions and may therefore reverse some he-
matopoietic cell dysfunctions observed in GHD patients.
Indeed, it has been observed that thymic function can be
significantly enhanced by GH therapy [48]. Additionally,
GH therapy was found to significantly increase the ex-
pression of several genes involved in signaling pathways of
hematopoietic and immune cells, including cytokines
(IL1A, IL1B, IL8, and ILF2) and chemokines (CCL4,
CXCL1, CXCL2, and CXCL16), which are associated with
cell proliferation and chemotaxis. Moreover, GH therapy
induced the gene expression of tRNA synthetase, a crucial
enzyme implicated in the synthesis of cellular components,
i.e., nucleic acids, contributing in cell cycle control, mRNA
transcription, splicing, and nuclear export of tRNAs [49].
Together, the above results imply that exogenous rhGH is
likely to induce significant changes in cell cycle regulation,
intracellular signaling, and cytokine production in HPCs
from GHD children.
We further analyzed the influence of GH deficiency on
gene expression changes in CD34? HPCs. Specifically, the
genes that were down-regulated due to GH deficiency
could be broadly clustered into the following categories:
cell cycle regulation and mitosis, hematopoietic cell lin-
eage development and differentiation, cell chemotaxis,
angiogenesis and endothelial cell migration, cytokine pro-
duction and secretion, cytokine–cytokine receptor interac-
tion, receptor signaling pathways, lipid metabolism, and
biosynthesis of cell components (Fig. 7b). The most down-
regulated gene in HPCs from GHD subjects was
prostaglandin-endoperoxide synthase-2 (PTGS2), which
acts both as a dioxygenase and a peroxidase, and thus is
involved in the inflammation as well as the stimulation of
mitosis [50]. Furthermore, the c-MYB gene encoding the
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proto-oncogene, which controls HSPC proliferation and
differentiation [51], was also significantly down-regulated
in GHD patients.. The above results demonstrate that GH
deficiency can down-regulate the expression of genes that
appear to be essential for cell cycle regulation, cell survival
and proliferation, and differentiation of HPCs. Importantly,
the changes in gene expression pattern found by our group
in circulating HPCs from GHD children after 6-month GH
therapy were also observed by other groups in mature PB-
derived mononuclear cells from GHD children treated with
GH for 1 or 3 months [52, 53]. In all analyses, GH treat-
ment was associated with expression changes of genes
involved in the processes such as cell function and meta-
bolism, cell cycle, and cell migration. In particular, Stevens
et al. observed that 1-month therapy with GH induced
changes in MAPK- and SOS-mediated signaling pathways
(e.g., IGF1) that are strongly related with cell growth and
proliferation [52]. Similarly, 3-month GH treatment sig-
nificantly induced expression of genes encoding regulators
of G-protein signaling (RGS1), nuclear receptors
(NRF4A2), and members of TNF-alpha family (TNFAIP3),
as well as genes implicated in GH signaling, including
SOCS1 [53]. In addition, Fernandez-Perez et al. revealed
that, among unique 163 genes differentially expressed in
PB-derived mononuclear cells collected before and after
1-month of GH treatment in adult GHD patients, there were
markedly expressed genes involved in SOCS-dependent
intracellular signaling cascade (ASB6) or implicated in
regulation of cell cycle progression (PSMD8), immune
response (IK), signal transduction (PABPN1), or mRNA
processing (PPP2R5C) [54]. Not surprisingly, the observed
gene expression changes strongly involve the IGF1 path-
way; therefore, the observed changes in gene expression in
different cell populations circulating in PB could reflect
both direct and indirect GH actions.
In conclusion, we report a direct cause and effect as-
sociation between GHD and hematopoiesis in children. Our
study demonstrates that CD34? HPCs are sensitive to the
pathophysiological conditions present in GHD and
therapeutic GH replacement lasting at least 6 months. Our
data also showed that GHD significantly impacts the pro-
liferative potential of HPCs and their differentiation into
erythroid-committed progenitors. Of note, we consider this
work as an exploratory pilot study as the number of age-
and sex-matched patients was small. Our observations may
help improve the understanding of the interactions between
rhGH and human hematopoiesis.
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